Hershey Co (HSY) Stock Price Today
Aura AI Summary
Key Stats
- $34.32BMarket Cap
- 1,970,425Volume
- Consumer StaplesSector
- $236.2852W High
- $157.6152W Low
- 136 DaysTypical Hold Time
- $39.46BEnterprise Value
- 3.4%Div Yield
- -Trading Activity
Track Hershey Co (HSY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Hershey Co has traded between a low of $157.61 and a high of $236.28, highlighting its annual price range. Buy and sell Hershey Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Most Recent News
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

Stocks tumble as Iambic Therapeutics and TCGX Acquisition lead losses amid IPO and merger news.
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.